Aldeyra’s NS2 eye drug succeeds in phase IIa study to treat allergic conjunctivitis
NS2 is an aldehyde-binding small molecule based on a platform technology that centers on trapping aldehydes, which are toxic and pro-inflammatory mediators of several diseases. It lowers aldehyde
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.